Bacteria in colitis associated cancer development
Download from source ↗Dataset overview
Bacterial Oncotraits Rather than Spatial Organization Are Associated with Dysplasia in Ulcerative Colitis.
Abstract
<h4>Background and aims</h4>Colonic bacterial biofilms are frequently present in ulcerative colitis [UC] and may increase dysplasia risk through pathogens expressing oncotraits. This prospective cohort study aimed to determine [1] the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and [2] the relation of bacterial composition with biofilms and dysplasia risk.<h4>Methods</h4>Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Oncotraits [FadA of Fusobacterium, BFT of Bacteroides fragilis, colibactin [ClbB] and Intimin [Eae] of Escherichia coli] were assessed in faecal DNA with multiplex quantitative polymerase chain reaction [qPCR]. Biopsies were screened for biofilms [n = 873] with 16S rRNA fluorescent in situ hybridiation. Shotgun metagenomic sequencing [n = 265], and ki67-immunohistochemistry were performed. Associations were determined with a mixed-effects regression model.<h4>Results</h4>Biofilms were highly prevalent in UC patients [90.8%] with a median persistence of 3 years (interquartile range [IQR] 2-5 years). Biofilm-positive biopsies showed increased epithelial hypertrophy [p = 0.025] and a reduced Shannon diversity independent of disease status [p = 0.015], but were not significantly associated with dysplasia in UC: adjusted odds ratio [aOR] 1.45, 95% confidence interval [CI] 0.63-3.40. In contrast, ClbB independently associated with dysplasia [aOR 7.16, 95% CI 1.75-29.28], and FadA and Fusobacteriales were associated with a decreased dysplasia risk in UC [aOR 0.23, 95% CI 0.06-0.83, p <0.01].<h4>Conclusions</h4>Biofilms are a hallmark of UC; however, because of their high prevalence are a poor biomarker for dysplasia. In contrast, colibactin presence and FadA absence independently associate with dysplasia in UC and might therefore be valuable biomarkers for future risk stratification and intervention strategies.
doi:10.1093/ecco-jcc/jjad092 ↗ PMID 37243505 ↗ PMC10673813 ↗
Study facts
- Organism
- —
- Platform
- —
- Age group
- —
- Disease groups
- Non-IBD controls, Ulcerative colitis
- Anatomical sites
- —
Data availability
Specific data assets have not been resolved from the source yet — see the source repository below for the full file listing.
Strengths & limitations for reuse
Strengths
- Participant counts are documented
- Sample counts are documented
Limitations
- Not documented: raw reads are advertised
- Not documented: feature/otu tables are advertised
- Not documented: taxonomic tables are advertised
Extraction evidence & provenance
Each extracted field is shown with the source excerpt and location used to resolve it.
Assay
| Field | Value | Evidence |
|---|---|---|
assay.sequencing_type |
shotgun_metagenomics from source |
Shotgun metagenomic sequencing [n=265] Section |
Cohort
| Field | Value | Evidence |
|---|---|---|
cohort.disease_activity_metadata_available |
True |
Endoscopic assessment of the severity of inflammation was performed for each biopsy location using the endoscopic Mayo score. Section |
cohort.non_ibd_controls |
35 from source |
collected from 80 UC patients and 35 controls Section |
cohort.study_design |
longitudinal inferred |
We performed a prospective cohort study and employed an additional retrospective longitudinal arm Section |
cohort.total_participants |
115 computed |
Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Section |
cohort.treatment_exposure_documented |
True |
68.8% used aminosalicylates and 17.5% were on biologic therapy. Section |
cohort.ulcerative_colitis_participants |
80 from source |
collected from 80 UC patients and 35 controls Section |
Data_Assets
| Field | Value | Evidence |
|---|---|---|
data_assets.raw_reads |
False |
Raw sequencing data with human reads will not be publicly available because of General Data Protection Regulation [GDPR]. Section |
Specimens
| Field | Value | Evidence |
|---|---|---|
specimens.body_site |
ascending and descending colon |
From all patients, biopsies were taken from the ascending and descending colon Section |
specimens.inflamed_status_available |
True |
Endoscopic assessment of the severity of inflammation was performed for each biopsy location using the endoscopic Mayo score. Section |
specimens.longitudinal_sampling |
True |
additional retrospective longitudinal arm for in-depth biofilm characterisation Section |
specimens.number_of_samples |
265 from source |
Shotgun metagenomic sequencing [n=265] ... were performed. Section |
specimens.sample_type |
mucosal_biopsy |
Metagenomic shotgun analysis of left- and right-sided biopsies revealed that the bacterial composition in UC patients differed Section |